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BDNF and its receptor TrkB have important roles in neurodevelopment, neural 2	
plasticity, learning and memory. Alterations in TrkB expression have been described in 3	
different CNS disorders. Therefore, drugs interacting with TrkB, specially agonists, are 4	
promising therapeutic tools. Among them, the recently described 7,8-dihydroxyflavone 5	
(DHF), an orally bioactive compound, has been successfully tested in animal models of 6	
these diseases. Recent studies have shown the influence of this drug on the structure 7	
of pyramidal neurons, specifically on dendritic spine density. However, there is no 8	
information yet on how DHF may alter the structural dynamics of these neurons (i.e. 9	
real-time study of the addition/elimination of dendritic spines and axonal boutons). In 10	
order to gain knowledge on these effects of DHF, we have performed a real-time 11	
analysis of spine and axonal dynamics in pyramidal neurons of barrel cortex, using 12	
cranial windows and 2-photon microscopy during a chronic oral treatment with this 13	
drug. After confirming TrkB expression in these neurons, we found that DHF increased 14	
the gain rates of spines and axonal boutons, as well as improved object recognition 15	
memory. These results help to understand how the activation of the BDNF-TrkB 16	
system can improve basic behavioural tasks through changes in the structural 17	
dynamics of pyramidal neurons. Moreover, they highlight DHF as a promising 18	






The receptor of the brain-derived neurotrophic factor (BDNF), the tropomyosin 2	
receptor kinase B (TrkB), is expressed in most of the pyramidal neurons of the 3	
neocortex (Miller and Pitts 2000). The interaction of this neurotrophin and its receptor is 4	
not only essential for neural growth and survival, but also for neural plasticity (Yoshii 5	
and Constantine-Paton 2010), in which, among other functions, it promotes synaptic 6	
potentiation through the establishment of LTP in the cerebral cortex (Kang et al. 1997; 7	
Escobar et al. 2003). However, its malfunction underlies the etiopathology of different 8	
neuropsychiatric disorders, including major depression (Castrén and Rantamäki 2010) 9	
or schizophrenia (Pandya et al. 2013). Therefore, it is important to develop strategies to 10	
activate TrkB that could be clinically implemented. In this regard, the 7,8-11	
dihydroxyflavone (DHF), a potent and specific TrkB agonist, has recently emerged as a 12	
promising therapeutic treatment (Jang et al. 2010). This drug is especially interesting 13	
because it is orally bioactive and can easily cross the blood-brain barrier (Du and Hill 14	
2015). In fact, recent research has already proven its effectiveness in animal models of 15	
Parkinson’s disease (Jang et al. 2010), Alzheimer’s disease (Zhang et al. 2014; 16	
Castello et al. 2014), major depression (Zhang et al. 2015; Zhang et al. 2016) or 17	
schizophrenia (Yang et al. 2014). Given the involvement of BDNF/TrkB in neuronal 18	
plasticity it is thought that DHF would increase it. However, the neurobiological bases 19	
of these positive effects on plasticity are still not fully understood. 20	
Although neural plasticity can be studied from different points of view, changes in 21	
neuronal structure should represent the rearrangement of synapses and, therefore, in 22	
the neural circuitry (Caroni et al. 2012). Regarding this, different studies have shown 23	
that DHF reverts the structural alterations found in the pyramidal neurons of certain 24	
animal models of CNS disorders: It returns to control levels the decreased spine 25	
density in mouse models of Alzheimer’s disease (Castello et al. 2014) and major 26	
depression (Zhang et al. 2015). Moreover, in healthy rats, DHF reverts the functional 27	
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decline produced by ageing, probably by increasing the spine density in the amygdala, 1	
hippocampus and prefrontal cortex (Zeng et al. 2012a). However, the study of 2	
structural plasticity goes beyond these analyses of dendritic spine density. With the 3	
emergence of imaging techniques for examining structural dynamics we have 4	
increased our knowledge on how neuronal networks are finely modulated by different 5	
treatments. In order to perform such experiments, it is necessary to chronically implant 6	
cranial windows in mice that express a fluorescent protein in their pyramidal neurons 7	
and to image these cells in real-time with a 2-photon microscope (Holtmaat et al. 8	
2009). These studies give us information in real-time of the addition, elimination or 9	
stability of dendritic spines and axonal boutons, such as the en passant boutons (EPB), 10	
in the same structure throughout an entire experiment (Holtmaat and Svoboda 2009; 11	
Chen and Nedivi 2013). They also allow us to distinguish transient alterations from 12	
persistent ones. This represents valuable information for understanding long lasting 13	
changes in the network (Holtmaat et al. 2006; Holtmaat and Svoboda 2009; Chen and 14	
Nedivi 2013), since the spines that remain stable for at least 4 days are the ones that 15	
always bear a synapse (Knott et al. 2006). In addition, these analyses are longitudinal 16	
and consequently may allow us to establish the proper treatment course for further 17	
clinical research on the drug tested. Alterations in structural dynamics have been 18	
proposed to underlie adaptation to changing environments, as has been shown after 19	
sensory deprivation in both excitatory (Hofer et al. 2009; Holtmaat and Svoboda 2009; 20	
Cane et al. 2014) and inhibitory (Chen et al. 2011c; Chen et al. 2011b; Keck et al. 21	
2011; Chen et al. 2012; van Versendaal et al. 2012) circuits.  22	
We have developed an experiment to understand how BDNF/TrkB interaction 23	
regulates in real-time the neuronal structural plasticity of pyramidal neurons in the 24	
barrel cortex and affects behaviors presumably dependent on this cortical region. 25	
Thy1-YFP transgenic mice, in which a subset of layer V pyramidal neurons 26	
constitutively express EYFP (Feng et al. 2000; Porrero et al. 2010) were used in this 27	
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study. We have imaged in real-time the same dendrites and axons before and during a 1	
14-day treatment with DHF and have tested anxiety-related behaviors and object 2	
recognition memory. 3	
 4	
MATERIAL AND METHODS 5	
Animals and 7,8-Dihydroxyflavone treatment 6	
Twenty-six adult transgenic mice Thy1-YFP, line H (Jackson Laboratories; Bar 7	
Harbor, Maine, USA) were used for all the experiments (Fig. 1a). In this strain, layer V 8	
cortical pyramidal neurons are densely labeled with EYFP (Feng et al. 2000) (Fig. 1b). 9	
Two of these mice were destined to the analysis of TrkB expression in Thy1-YFP 10	
expressing neurons (see below). Cranial windows were implanted in the remaining 24 11	
mice to study in real-time the effects of the treatment with the TrkB agonist 7,8-12	
Dihydroxyflavone (DHF, Abcam, Cambridge, UK) on the structural dynamics of Thy1-13	
YFP expressing neurons (Figs. 1a-1d). The behavior of these 24 animals was also 14	
evaluated on the open field arena and the novel object recognition test (Figs. 1e&f). 15	
However, only mice carrying cranial windows that remained clear during the whole 16	
experiment were taken into account in both the structural and behavioral analyses (6 in 17	
the control group and 9 in the DHF group). These mice were subjected to 3 18	
consecutive 2-photon imaging sessions before starting the DHF or vehicle treatment 19	
and 3 sessions during the treatment (see below and Fig. 1). The oral treatment with 20	
DHF or with vehicle solution started right after the end of the 3rd imaging session. 21	
Eighty microliters of a DHF (100 mg/ml in DMSO; Abcam) or vehicle solution (DMSO; 22	
Sigma-Aldrich, San Luis, MO, USA) were added to 100 ml of drinking water containing 23	
1% of sucrose (pH=7.4). These solutions were replaced every 3-4 days during the 14 24	
days of duration of the treatment and bottle content was measured to monitor liquid 25	
intake. Animals were also weighted every 3-4 days. The average liquid intake was 2 26	
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ml/day/mouse and the average weight of mice was 32 g. Therefore, DHF dose was 1	
approximately 5mg/kg/day. 2	
Animals were reared in groups of 3-4, in standard-size polycarbonate cages, in 3	
a temperature- and humidity-controlled environment and maintained on a 12 h 4	
light/dark cycle with food and water available ad libitum.  5	
All animal experimentation was conducted in accordance with the Directive 6	
2010/63/EU of the European Parliament and of the Council of 22 September 2010 on 7	
the protection of animals used for scientific purposes and was approved by the 8	
Committee on Bioethics of the Universitat de València. Every effort was made to 9	
minimize the number of animals used and their suffering. 10	
TrkB immunohistochemistry 11	
Thy1-YFP mice destined to the analysis of TrkB expression in YFP expressing 12	
pyramidal neurons were transcardially perfused with 4% paraformaldehyde solution 13	
and their brains were cut in 50 µm-thick coronal sections using a vibratome (Leica 14	
VT1000E, Leica, Wetzlar, Germany). Free-floating sections were first blocked with 10% 15	
normal donkey serum solution and then incubated overnight at room temperature with 16	
goat anti-TrkB receptor primary antibody (1:400; R&D systems, Minneapolis, MN, 17	
USA). The day after, sections were incubated with donkey anti-goat secondary 18	
antibody conjugated with AlexaFluor®647 (1:400, LifeTechnologies, Carlsbad, CA, 19	
USA) for 2 hours and then mounted on slides and covered with mounting media (Dako, 20	
Glostrup, Denmark). Images were acquired with a Leica TCS SPE confocal microscope 21	
using a 63X oil objective and 2X digital zoom magnification (Fig. 2). 22	
Cranial window implantation 23	
To allow long-term high-resolution imaging of in vivo neuronal morphology, a cranial 24	
window was unilaterally implanted over the primary somatosensory cortex (barrel field; 25	
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Bregma -1.5 mm, Lateral 3.5 mm) of 24 Thy1-YFP mice (2-month-old). Animals were 1	
first anesthetized with an intraperitoneal injection of a mixture of ketamine (50 mg/kg; 2	
Imalgene, Merial, Lyon, France) and medetomidine (1 mg/kg; Sedator, Dechra, 3	
Barcelona, Spain); carprofen (5 mg/kg; Rimadyl, Pfizer, New York, NY, USA) was also 4	
injected intraperitoneally to avoid inflammation, and a subcutaneous injection of 5	
butorphanol (5 mg/kg; Torbugesic, Pfizer) was administered to avoid any suffering 6	
during and after the surgery. Animals were placed afterwards in a stereotaxic device. 7	
After cutting a flap of skin (approx. 1 cm2), the periosteum was gently removed from the 8	
skull using fine tweezers and the temporalis muscle was separated with a blunt 9	
spatula. A thin layer of cyanoacrylate was applied to the temporalis muscle, wound 10	
margins and skull, with the exception of the region of interest in the skull. Once it dried, 11	
a thin layer of dental acrylic was applied on top of the glue. A circular groove around 12	
the area of interest was pierced using a biopsy punch with a diameter of 3 mm 13	
(Aesthetic Group, Puiseux-le-Hauberger, France) leaving an island of skull in the 14	
center that was removed afterwards using the tip of sharp forceps. This technique 15	
was chosen because it produces less harm in the underlying nervous tissue than 16	
the classical drill technique used in open-skull surgeries. However, further 17	
assays (study of the presence of reactive glia) were performed in order to 18	
confirm the absence of damage. To clean the area, drops of cortex buffer (Holtmaat 19	
et al. 2009) were applied regularly after the island of skull was removed. Finally, the 20	
unblemished dura was covered with a circular coverglass (3 mm diameter, 1 mm thick; 21	
Harvard Apparatus, Holliston, MA, USA) and the borders were sealed with 22	
cyanoacrylate and dental acrylic. Finally, animals were intraperitoneally injected with 23	
atipamezole (0.5 mg/kg; Antisedan, Esteve, Barcelona, Spain) to revert the anesthesia 24	
and returned to individual cages for recovery. The day after surgery, mice were 25	
returned to their home cages (social rearing) and left undisturbed for 2 weeks to allow 26	
complete recovery before imaging. 27	
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Assessment of the presence of reactive astroglia and microglia in the 1	
parenchyma underlying cranial windows 2	
Because the employment of biopsy punches to perform the cranial 3	
windows is a novel technique, two animals were processed to search for gliosis 4	
under the cranial window. The ipsilateral hemispheres to the cranial window of 5	
these mice were cut in 100-µm-thick coronal sections using a vibratome (Leica 6	
VT1000E, Leica), and the slices where processed to detect astroglia and 7	
microglia and the presence of reactive gliosis. Therefore, an 8	
immunohistochemistry assay was performed using markers for these types of 9	
cells. The same immunohistochemistry protocol described before was applied 10	
using as primary antibody the mouse IgG anti-S100 (1:1000, Sigma-Aldrich), a 11	
marker of astrocytes, and the biotin-conjugated lectin from Lycopersicon 12	
esculentum (1:50, Sigma-Aldrich), a marker of microglial cells. These markers 13	
were subsequently detected with goat anti-mouse IgG AlexaFluor®405 14	
(LifeTechnologies) and Streptavidin AlexaFluor®647 (LifeTechnologies) 15	
respectively. Slices were mounted on slides and covered with mounting media 16	
(Dako). Images were acquired using an Olympus FV1000 confocal microscope 17	
(Olympus, Tokyo, Japan) using a 60X oil objective and 1.3X digital zoom 18	
magnification. 19	
In vivo 2-photon imaging 20	
In vivo 2-photon imaging was achieved using an Olympus FV1000MPE microscope 21	
and its acquisition software (Olympus fluoview FV1000 v4.0.1.10, Olympus). The light 22	
source for 2-photon excitation was a commercial Ti:Sapphire laser (Mai-Tai HP 23	
DeepSee, Spectra Physics, Santa Clara, CA, USA). The excitation wavelength was set 24	
to 930 nm, with the excitation signal passing through an XLPLN25XWMP 25×/1.05 NA 25	
water-immersion objective (Olympus) and collected after a barrier filter by a 26	
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photomultiplier tube. The same cells could be identified and re-imaged for up to 20 1	
days using local fiduciary landmarks of the brain's surface vasculature. 2	
Image acquisition and analysis 3	
Adult mice (3-month-old) previously implanted with cranial windows were anesthetized 4	
with a mixture of ketamine (50 mg/kg; Imalgene, Merial) and medetomidine (1 mg/kg; 5	
Sedator, Dechra). Anesthesia was monitored by breathing rate and foot-pinch reflex. A 6	
total number of 15 mice presented a cranial window clear enough to complete all the 7	
imaging sessions. The head was positioned in a custom-made stereotaxic restraint. In 8	
the first imaging session, a panoramic z-stack was obtained in order to identify all the 9	
landmarks and regions of interest (512x512, z step-size 3 µm). Afterwards, 4 regions of 10	
interest were imaged per animal, each of them containing several dendrites and axons. 11	
These images were obtained with a digital zoom of 8X and comprised only layer I of 12	
the neocortex (512x512, z step-size 1 µm). Raw scanner data were processed in 13	
ImageJ (National Institutes of Health, Bethesda, MD, USA) and the 6 four-14	
dimensional (x, y, z, t) stacks of each animal were analyzed blind to the experimenter 15	
using this software.  16	
The real-time analysis included 6 dendrites and 6 axons of pyramidal cells per mouse, 17	
so that each animal would present uniform data regarding their dynamics, resulting in a 18	
total of 344 axonal boutons and 1699 dendritic spines in 90 axons and 90 dendrites 19	
(approximately 23 axonal boutons and 113 spines per animal). The regions of interest 20	
were arbitrarily named with a two-letter code to avoid any bias from the experimenter. 21	
Dendritic and axonal branches were distinguished by their morphology. Axons were 22	
typified as thin tubular processes, often scattered with varicosities (EBP) whose 23	
fluorescence were at least 2 times higher than that of the axonal backbone. Dendrites 24	
were distinguished by thicker diameters (generally >2 µm), smooth, gradually tapering 25	
processes, and characteristic branching patterns. Their dendritic spines were scored 26	
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manually as membranous protrusions obeying to two criteria: (1) they should be 1	
unilateral and (2) they should be longer than 0.8 µm, measured from the emergence of 2	
the spine to its tip. 3	
In order to study the structural dynamics, several parameters were analyzed. Gain, loss 4	
and stability rates were respectively the new, lost and stable spines/EPB in a given 5	
time point related to the previous number of spines/EPB (Fig. 1d). The turnover rate 6	
was the sum of the gain and loss rates divided by 2, which provided us with a more 7	
accurate idea about the dynamism. The stable rates were also studied because of their 8	
importance for the network, since structures lasting longer than 4 days have been 9	
shown to always bear at least one synapse (Knott et al. 2006; De Paola et al. 2006; 10	
Grillo et al. 2013). The stable gain rate represented the number of structures (spines 11	
and EPBs) added in a time point and lasting for at least 4 days (2 consecutive imaging 12	
sessions), related to their previous number. Likewise, the stable loss rate of 13	
spines/EPB represented the structures that have lasted longer than 4 days (2 14	
consecutive imaging sessions) and were then lost, related to their previous number 15	
(Fig. 1d). The turnover rate of stable spines/EPB was the sum of the gain and loss 16	
rates of stable spines/EPB divided by 2 and, again, provides us with a more accurate 17	
idea about the dynamism. After all the dynamic rates were calculated, they were 18	
divided by their first data point in order to normalize them and were multiplied by 100 to 19	
be expressed in percentages –related to the previous number- of dendritic spines or 20	
EPB that have been gained, lost, remained stable or experience some turnover. 21	
Therefore, the first data point of each data set is set to 100%: -8d/-4d when 22	
addressing the “normal” dynamic parameters, -8dà -4d/0d when addressing the 23	
loss rate of stable spines/EPB, -8d/-4dà0d in the case of spines/EPB that are 24	
gained and remain stable, and -8dà -4d/-4dà0d] when studying the turnover rate 25	
of stable spines/EPB.  26	
Spine volume analysis 27	
11	
	
It has already been shown that the fluorescence intensity of a spine head is positively 1	
correlated to its volume (Holtmaat et al. 2005). In fact, increases in spine volume are 2	
related to potentiation via LTP, whereas the dendritic shaft remains unaffected 3	
(Matsuzaki et al. 2004). Therefore, we analyzed whether the dendritic spines that were 4	
stable throughout the experiment would alter their volume during the DHF treatment. 6 5	
stable spines were studied per animal (a total of 90 spines). This procedure diminished 6	
intra-group variability. Additionally, the images should not contain saturated pixels in 7	
order to allow for the detection of variations in fluorescence intensity (pixel value). 8	
Because the intensity of the overall image could be altered due to changes in the 9	
conditions of 2-photon imaging or the cranial window, the intensity of the dendritic 10	
shaft, which volume remains unaffected, was also taken into account (Svoboda et al. 11	
1996; Trachtenberg et al. 2002). We then chose the focal plane with the highest 12	
integrated fluorescence across the spine and calculated the ratio between its mean 13	
pixel value and the mean pixel value of a similar portion of the adjacent dendritic shaft. 14	
In addition, the standard deviation of the point spread function was calculated 15	
for each spine using ImageJ (National Institutes of Health), and these data were 16	
statistically compared to ascertain our measures were not influenced by 17	
uncontrolled factors. 18	
Behavioral tests 19	
Twenty-four hours before starting the Novel Object Recognition (NOR) test, all animals 20	
were exposed for 10 minutes to the empty apparatus (Open Field chamber, OF, 21	
40x40cm) (Figs. 1&3). This habituation procedure was also used to evaluate the 22	
locomotor activity and the anxiety levels of the animals (ANY-maze video tracking 23	
system v4.98; Stoelting Europe, Dublin, Ireland), in order to remove from the 24	
experiment those mice showing abnormal behaviors. The video tracking system 25	
provided automated measures of the total distance travelled and mean speed, to study 26	
locomotor activity, and number of entries and time spent in the periphery of the arena, 27	
12	
	
for the measurement of anxiety and thigmotaxis (a valid index of anxiety in mice; Simon 1	
et al. 1994). The periphery zone of the arena was defined as the area located between 2	
0 and 6 cm from the walls of the apparatus. All animals were subjected to the OF (day -3	
1 and day 12) and NOR (day 0 and day 13) tests before and after the treatment with 4	
DHF or vehicle solution (Fig. 1). 5	
Every NOR test was divided in 2 sessions or phases: “familiarization” and “test” (Figs. 6	
1&4). During the familiarization phase, two copies of an object (familiar object) were 7	
placed in 2 opposite corners of the OF arena (5 cm away from the walls) and the 8	
animal was allowed to explore the arena for 4 minutes. During the test phase (30 9	
seconds after the familiarization phase), a duplicate of the familiar object and a novel 10	
object were placed in opposite corners of the arena and mice were allowed again to 11	
explore the open field arena for 4 minutes. Between sessions, the apparatus and all 12	
objects were cleaned with 70% ethanol solution to eliminate odor cues. In this 13	
experiment, all mice participated in 2 familiarization phases and 2 test phases, one for 14	
every level of perceptual difficulty (“Easy” and “Difficult”; Fig. 1) (Burke et al. 2011; 15	
Burke et al. 2012). In the “Easy task” the novel and familiar object did not share any 16	
common features, this is, they were different in shape, texture and size (Figs. 4a&b). 17	
For the “Difficult task”, the objects were identical in shape and color and only 1 of the 18	
sides of the objects had a different texture (Figs. 2a&b).  This difficult task was 19	
designed to analyze object recognition dependent on the barrel cortex. Object 20	
exploration was scored whenever the mouse sniffed the object or touched the object 21	
while looking at it (when the distance between the nose and the object was less than 2 22	
cm). Climbing onto the object or chewing the object did not quantify as exploration 23	
(Leger et al. 2013). The time spent exploring each object was recorded during the 24	
habituation and test phases in both levels of perceptual difficulty (easy and difficult). 25	
For every animal, the data of the test phase was normalized with the data of the 26	
habituation phase to calculate afterwards the discrimination ratio (DR) in the easy and 27	
13	
	
difficult task: time spent exploring the novel object divided by the time spent exploring 1	
both the novel and familiar objects (Bevins and Besheer 2006). 2	
Statistics 3	
All the dynamic parameters were normalized to time -8d (first imaging session) prior to 4	
the statistical analysis, thus converting all the dynamic data in percentages related 5	
to the previous data point and being the first one 100%. For all the longitudinal 6	
studies, a repeated-measures ANOVA was performed with treatment (DHF vs control) 7	
as between-subjects factor and time (imaging sessions) as within-subjects factor, 8	
followed by post hoc tests (Fisher’s least significant difference) for pairwise 9	
comparisons. The unit of observation was always the animal, and each data point in 10	
the linear analysis of structural dynamics was the mean of the dynamics of 6 different 11	
structures (dendrites, axons or dendritic spines), which diminished the intra-group 12	
variability. Only mice that finished all the imaging sessions were taken into account and 13	
the same animals with completed structural analysis were used to analyze the 14	
behavioral tests (6 control and 9 DHF). 15	
Behavioral data were analyzed using repeated measures ANOVA followed, when 16	
appropriate, by post-hoc test. When analyzing the OF data, treatment (DHF vs control) 17	
and time (before vs after DHF-treatment) were considered as a between-subjects 18	
and within-subjects factors respectively. In the NOR test, an extra within-subjects factor 19	
(Difficulty: easy vs difficult task) was added to the analysis. 20	
All the statistical analyses were performed using the statistical package SPSS v22.0 21	
(IBM) and graphs were created using GraphPad Prism 6. Data in the figures were 22	





Pyramidal neurons of the barrel cortex express TrkB in their somata, dendritic 2	
spines and axonal boutons 3	
We performed immunohistochemistry to demonstrate that TrkB was expressed by 4	
pyramidal neurons of the barrel cortex in Thy1-YFP mice (Fig. 2). We found that, 5	
indeed, TrkB expression puncta were found inside and in close apposition to axonal en 6	
passant boutons (Fig. 2b), the cell somata (Fig. 2c1), as well as in spine heads (Fig. 7	
2c2). 8	
Cranial windows performed with the biopsy punch do not elicit gliosis 9	
In order to detect whether our cranial windows were producing damage in the 10	
underlying neocortical parenchyma, we studied the distribution and morphology 11	
of astrocytes and microglia with immunohistochemistry. We observed that both 12	
cells displayed similar density and morphology when comparing layer I and V 13	
from regions below the cranial window with regions of the neocortex located 14	
outside the influence of the surgery (Supp. fig 1). No reactive astrocytes or 15	
microglia were observed in any of the regions studied.  16	
DHF treatment does not affect locomotion or anxiety-related behavior 17	
We analyzed the distance travelled, mean speed and immobility time during the OF 18	
test, before (day-1) and after (day 12) vehicle or DHF treatments, as an index of 19	
locomotor activity (Figs. 3a&b). Although decreased locomotion was found to occur 20	
after the treatment (distance travelled, mean speed and immobility time; Fig. 3b), no 21	
statistically significant differences were found between DHF and vehicle-treated mice 22	
(distance travelled at day -1 or at day 12, Figs. 3a&b; mean speed at day -1 or at day 23	
12; Fig. 3b; and immobility time at day -1 or day 12, Fig. 3b). 24	
15	
	
A similar situation occurred when we analyzed anxiety-related behavior (Fig. 3c), with 1	
an apparent decrease of anxiety after treatment (border distance, border time and line 2	
crossings), but no statistically significant differences among DHF and control groups 3	
were found. 4	
DHF treatment improves object recognition  5	
When we analyzed the discrimination ratio (time spent exploring the novel object/ time 6	
spent exploring both objects), repeated measures ANOVA showed a statistically 7	
significant effect of time (before vs after treatment: p=0.013, Figs. 4a&b) and 8	
Time*Treatment interaction (0.002) only for the difficult condition. Therefore, multiple 9	
pairwise comparisons could only be performed for the difficult condition. We found that 10	
the DHF group of mice did not show statistically significant differences with the control 11	
group before treatment (day 0) but showed an increased object discrimination ratio 13 12	
days after treatment in the difficult task. Therefore, only DHF-treated mice showed 13	
increased object discrimination ratio in the difficult task (Fig 4b). 14	
Chronic DHF treatment alters the dynamics of axonal boutons in pyramidal 15	
neurons of the barrel cortex  16	
Different dynamic and stability parameters were analyzed and found altered during the 17	
DHF treatment (Fig. 5). The gain rate of EPB was altered during the experiment in 18	
both experimental and control conditions, although in a different direction (Fig. 5b). In 19	
control conditions the gain rate diminished gradually throughout the experiment (i.e. 20	
the rate by which new spines were formed was progressively decreasing), 21	
whereas in DHF-treated mice it was firstly increased and finally decreased to baseline 22	
levels. The difference between groups reached its peak in the middle of the DHF 23	
treatment (4d/8d). Neither the loss rate nor the turnover rate were altered during the 24	
experiment. However, in the DHF group the stability rate of their EPB decreased 25	
16	
	
gradually through the treatment (i.e. the rate of EPB that remained stable from one 1	
time point to the next one was reduced progressively during the experiment). 2	
We next asked whether the stable EPB (those that last longer than 4 days) 3	
presented altered dynamics due to the DHF treatment, and found several interesting 4	
variations (Fig. 5c). First, the gain rate of stable EPB increased rapidly only in the 5	
beginning of the DHF treatment, which means that the rate by which EPB were 6	
formed and became stable (lasting longer than 4 days) was increased right after 7	
the beginning of DHF treatment. By contrast this rate remained unchanged in control 8	
conditions. Second, the loss rate of stable EPB (those that last at least 4 days, but 9	
are lost afterwards) increased gradually throughout the experiment in both conditions 10	
(i.e. the rate of disappearance of stable EPB increased progressively through the 11	
DHF and control conditions). However, in the DHF-treated mice this increase was 12	
more consistent, and there was a trend towards an increase in the DHF group in the 13	
middle of the treatment (0dà4d/8d) when compared with the control group. Finally, the 14	
turnover rate of stable EPB was increased in the beginning of the experiment in control 15	
conditions, which means that right after the start of the real-time imaging 16	
sessions the rate by which stable EPB were gained and lost rose; whilst in the 17	
DHF group this increase was significant from its baseline to the end of the DHF 18	
treatment. 19	
Chronic DHF treatment alters the dynamics of dendritic spines in pyramidal 20	
neurons of the barrel cortex  21	
In order to further understand the dynamics of pyramidal neurons under the influence 22	
of DHF, we analyzed the dendritic spine dynamics throughout the treatment (Fig. 6b). 23	
We found that the gain rate rapidly increased in the beginning of the experiment but 24	
later decreased to baseline and control levels (i.e. the rate by which spines were 25	
appearing increased right after the beginning of the experiment and later 26	
returned to control levels). There was also a trend towards an increase in the DHF 27	
17	
	
group in the middle of the treatment (4d/8d) when compared with the control group. 1	
The turnover rate was first increased in DHF animals, to return finally to control and 2	
baseline levels (i.e. the rate of spine addition and elimination increased until 4 3	
days after the beginning of the treatment and decreased thereafter). 4	
Furthermore, the loss rate increased in the beginning of the treatment only in 5	
control conditions, whereas the stability rate was reduced in both Control and DHF 6	
groups, although more prominently so in the former. 7	
Chronic DHF treatment protects stable pyramidal spines from dynamic changes  8	
We next asked whether the stable spines (those that last longer than 4d) had their 9	
dynamics altered under the DHF treatment (Fig. 6c). The gain rate remained 10	
unaltered, meaning that the rate of appearance of dendritic spines did not 11	
change. However, the loss rate and the turnover rate of stable spines varied in control 12	
conditions. The loss rate of stable spines increased throughout the experiment (i.e.  13	
the rate by which stable spines were disappearing progressively increased). 14	
These increases were also significant when comparing DHF and Control groups 15	
(0dà4d/8d and 4dà8d/12d), and there was also a trend towards an increase at the 16	
beginning of the treatment (-4dà0d/4d). Similarly, the turnover rate of stable spines 17	
was altered only in control conditions, first increasing and later returning to baseline 18	
levels, which means that the rate of addition and elimination of stable spines 19	
increased until the beginning of the vehicle treatment and decreased thereafter. 20	
There were also trends towards an increase when comparing both groups in the middle 21	
of the treatment (-4dà0d/0dà4d and 0dà4d/4dà8d). 22	
The volume of pyramidal spines remains unaltered throughout the DHF 23	
treatment  24	
In order to better understand the increases in the loss rate of stable spines, and 25	
alterations in the turnover rate, only in control conditions; we estimated the 26	
18	
	
volume of the spines that were present throughout the entire experiment (Fig. 7). 1	
These analyses were performed after confirming that the standard deviation of 2	
their point spread function did not statistically change, thus making sure the 3	
image analyzed was a reliable representation of the real object. Surprisingly, we 4	
found that the stable spines of the control group increased their volume whereas in 5	
DHF-treated mice this parameter remained stable. These increases were significant 6	




In the current study, we show, in real-time, how the structure of neocortical 2	
pyramidal neurons is altered during a chronic treatment with DHF, a TrkB agonist that 3	
has an important clinical potential (Fig. 8). Furthermore, we show that this treatment 4	
also enhances the recognition of complex objects. 5	
Our findings are in agreement with previous reports that showed the expression of 6	
TrkB in layer V in pyramidal neurons of the rat somatosensory cortex (Miller and Pitts 7	
2000). Moreover, we expand this knowledge by describing the presence of the receptor 8	
in the somata, dendritic spines and axonal boutons of these neurons in mice. We next 9	
asked whether a chronic activation of TrkB would alter the dynamics of these neuronal 10	
structures (gain, loss, stability rates of dendritic spines and axonal boutons in a 11	
longitudinal, chronic real-time study). We also wondered whether it would impact 12	
behaviors presumably dependent on this brain region. The gain rate of dendritic 13	
spines was increased 4 days after the beginning of the treatment, persisted after 8 14	
days and returned to baseline levels 12 days afterwards. Our findings are consistent 15	
with previous electrophysiological and structural findings, since LTP can be induced by 16	
TrkB activation (Minichiello et al. 2002; Minichiello 2009) and this form of synaptic 17	
plasticity promotes the apparition of dendritic spines in pyramidal neurons (Engert and 18	
Bonhoeffer 1999). In addition, pyramidal spine density increases in the rat 19	
hippocampus after BDNF administration (Tyler and Pozzo-Miller 2003), and also after a 20	
chronic treatment with DHF (Zeng et al. 2012b). However, all these previous findings 21	
were performed in post-mortem tissue and thus alterations in spine dynamics cannot 22	
be inferred.  23	
We have also studied the dynamics of stable spines, which are those present at 24	
least for 4 days (two consecutive imaging sessions). These spines are particularly 25	
important because they have been shown to always bear a synapse (Knott et al. 2006) 26	
and, therefore, are the ones modifying the network. The loss rate of stable spines 27	
20	
	
(spines lasting longer than 4 days, which are then lost) was incremented during 1	
our experiment only in the control group, whereas in the DHF treated animals there 2	
were no changes. Surprisingly, only in the control group, we have also found that the 3	
spines that remained stable during the whole experiment increased their volume. This 4	
enlargement in the remaining spines may be the consequence of the synaptic loss 5	
caused by the elimination of stable spines. Since increases in spine volume have been 6	
previously correlated to spine potentiation (Matsuzaki et al. 2004), we suggest that 7	
these remaining stable spines increase their volumes in order to compensate and 8	
maintain synaptically the circuit.  9	
We have also shown that the stability rate of dendritic spines was gradually 10	
reduced throughout the experiment, and this reduction was more pronounced in 11	
control animals. Likewise, the loss rate of dendritic spines was increased in the 12	
beginning of the experiment only in control mice. These two facts appear to be a 13	
consequence of real-time imaging: similar reductions in the stability rate have already 14	
been shown in the same mice strain that we used (Grutzendler et al. 2002). 15	
Consequently, it is likely that DHF might protect against the intrinsic damage that real-16	
time imaging produces, which is in agreement with the known neuroprotective 17	
properties of this drug against glutamate excitotoxicity (Chen et al. 2011a), neonatal 18	
hypoxia, ischemia (Uluc et al. 2013), degeneration of dopaminergic neurons in animal 19	
models of Parkinson’s disease (Luo et al. 2016) or staurosporine-induced apoptosis 20	
(Jang et al. 2010). 21	
The dynamics of axonal boutons were also analyzed before and during DHF 22	
treatment, showing increases in their gain rate 8 days after its onset. The dynamics of 23	
stable EPB (EPB that last longer than 4 days) were also analyzed and we found that 24	
their gain rate increases. Both results agree with the increases in axonal arborization, 25	
and consequently in the presynaptic surface, that BDNF infusion produces in other 26	
21	
	
species (Cohen-Cory and Fraser 1995; Lom and Cohen-Cory 1999; Bing et al. 2005; 1	
Granseth et al. 2013).  2	
We have also wondered whether a chronic treatment with DHF might improve 3	
sensory perception, which is mostly dependent on the barrel cortex, the region of our 4	
structural analysis. In order to study this, we have performed a modified NOR test with 5	
easy and difficult novel objects that varied in their texture, so that they may be mostly 6	
recognizable by their whiskers (Guić-Robles et al. 1989; Arabzadeh et al. 2005; Brecht 7	
2007; von Heimendahl et al. 2007). We have found that, indeed, animals treated with 8	
this drug displayed a higher discrimination ratio (time spent exploring the novel 9	
object/ time spent exploring both objects). These results agree with multiple studies 10	
correlating BDNF or TrkB manipulation with object recognition memory: BDNF 11	
expression has been positively linked to object recognition memory (Hopkins and Bucci 12	
2010), whereas a lesser activation of TrkB with anti-BDNF produces opposite results 13	
(Callaghan and Kelly 2013). In addition, DHF has already been shown to improve 14	
memory consolidation in both rats and mice also in a NOR test (Bollen et al. 2013). Our 15	
results go further and show that DHF also enhances object recognition behavior and 16	
sensory discrimination. Although our results suggest a connection between the 17	
effects of DHF treatment on neuronal structure and those on object recognition, 18	
it is possible that these two effects were concurrent but not connected. 19	
In conclusion, we provide real-time in vivo evidence of how the chronic activation 20	
of TrkB has beneficial behavioral effects in healthy animals and alters the structural 21	
plasticity and dynamics of neocortical pyramidal neurons. Our results also highlight the 22	
timeline of these structural changes, so that further research can pinpoint the optimal 23	
duration of the treatment. This is not unimportant since the malfunction of the BDNF-24	
TrkB system has been suggested to underlie several neuropsychiatric disorders, 25	
including Alzheimer’s disease or schizophrenia (Angelucci et al. 2005; Zuccato and 26	
22	
	
Cattaneo 2009), and currently its manipulation is being tested to provide new 1	






Fig. 1 Experimental design. (a) Timeline of the experimental procedure (b) To allow 3	
long-term and high-resolution imaging of in vivo neuronal morphology of pyramidal 4	
neurons, a cranial window was unilaterally implanted over the primary somatosensory 5	
cortex (S1; Bregma -1.5 mm, Lateral 3.5 mm) of Thy1-YFP mice (2-month-old). (c) 6	
Twenty days after surgery, 2-photon imaging sessions started. (d) The same dendrites 7	
and axons of every animal were imaged every 4 days to study spine and en passant 8	
bouton (EPB) dynamics. Every animal was recorded 3 sessions before and 3 sessions 9	
after DHF or vehicle treatment. Arrowheads point to dendritic spines or EPB with a 10	
color legend to clarify the effect on the dynamic parameters. White arrowheads point to 11	
spines/EPB that are present from the beginning of the experiment. Yellow arrowheads 12	
point to spines/EPB that are gained in that imaging session. Blue arrowheads point to 13	
those spines/EPB gained in the previous imaging session that have become stable. 14	
Red arrowheads point to EPB that were present in the previous imaging session but 15	
have disappeared in the current one.  (e) To test locomotion and anxiety related 16	
behavior, all animals were evaluated in the OF test, 24 hours before starting the 17	
treatment and on the 12th day of treatment. (f) A modified version of the novel object 18	
recognition test was used to evaluate recognition memory in mice before (day 0) and 19	
after DHF-treatment (day 13). Novel objects are indicated in the scheme with an 20	
asterisk (see material and methods’ section for further details) 21	
Fig. 2 TrkB receptor expression in Thy1-YFP expressing neurons. (a) Confocal 22	
panoramic view of a Thy1-YFP brain slice (Bregma -1.22 mm) immunostained for TrkB 23	
receptor (red). Our region of interest, the primary somatosensory cortex (S1) is 24	
delimited by the 2 dotted lines. Scale bar: 800 µm. (b) Magnified view (12x) of the 25	
squared section in A, showing TrkB expressing puncta (arrowheads in B1’) co-26	
localizing or in close apposition to YFP expressing axonal boutons (green). (c) 4.5x 27	
magnification of the squared area in A, showing layer V YFP-expressing pyramidal 28	
24	
	
neurons. TrkB receptors were found surrounding and in close apposition to the somata 1	
of these neurons (arrowheads in c1’) as well as to the spine head (c2’) 2	
Fig. 3 Open field test (OF). (a) Representative track-plot reports recorded during the 3	
10 min test sessions (ANY-maze). The central square was denominated “central zone” 4	
and the periphery, “border zone”. Observe the decrease in the distance traveled 5	
(purple line) by both groups (DHF and control) after the treatment (distance travel: 6	
p=1.2*10-5, mean speed: p=1.3*10-5, immobility time: p= 1.0*10-6). Locomotor activity 7	
(b) and anxiety-related behavior (c) were decreased in both groups after the treatment 8	
(border distance: p=0.051, border time: p=0.095, line crossings: p=0.008), but no 9	
significant differences were found between them. (***) p<0.001; (#) 0.1>p>0.05 10	
Fig. 4 Novel object recognition test (NOR). (a) Schematic drawings of the 2 types of 11	
NOR tests performed in our experiment and their phases (familiarization: 2 identical 12	
objects; test: 1 familiar and 1 novel object). (b) Photographs of the pairs of objects that 13	
were randomly used during the NOR test. The asterisk marks the novel object. (c) Bar 14	
graphs representing the discrimination ratio [time spent exploring the novel object/ time 15	
spent exploring both objects] for the easy and difficult tasks of the NOR test before 16	
(day 0) and after DHF treatment (day 13). Only DHF treated mice showed increased 17	
object discrimination ratio in the difficult task (p=0.017). Black Horizontal lines in 18	
graphs represent statistically significant effects of time (black), treatment (gray), or 19	
Time*treatment interaction (black, dashed) in a repeated-measures ANOVA (*p<0.05, 20	
**p<0.01, # 0.1<p<0.05) 21	
Fig. 5 Structural dynamics of EPB prior and during the chronic DHF treatment. 22	
(a) Real-time 2-photon images of a representative axon from a DHF-treated mouse. 23	
Arrows point to EPB with a color legend to clarify the effect on the dynamic parameters. 24	
White arrows point to EPB that are present from the beginning of the experiment. 25	
Yellow arrows point to EPB that are gained in that imaging session. Blue arrows point 26	
to those EPB gained in the previous imaging session that have become stable. Red 27	
25	
	
arrows point to EPB that were present in the previous imaging session but have 1	
disappeared in the current one. Scale bar: 5 µm (b) Graphs representing the different 2	
dynamic parameters. Gain rate: Longitudinal effects in the control group -8d/-4d 3	
vs 4d/8d: p=0.009; -4d/0d vs 4d/8d: p=0.09; and longitudinal effects on DHF 4	
group -8d/-4d vs 4d/8d: p=0.033; 0d/4d vs 4d/8d: p=0.047; 4d/8d to 8d/12d: 5	
p=0.019. Control vs DHF effects at 4d/8d: p=0.005. Stability rate: Longitudinal 6	
effects in the DHF group -4d/0d vs 8d/12d: p=0.018; 0d/4d vs 8d/12d: p=0.028. (c) 7	
Graphs representing the different dynamic parameters studied only on stable EPB 8	
(those lasting longer than 4 days). Gain rate of stable EPB: Longitudinal effects in 9	
the DHF group -8d/-4dà0d vs -4d/0dà4d: p=0.037. Loss rate of stable EPB: 10	
Longitudinal effects in the control group -8dà -4d/0d vs 4dà8d/12d: p=0.038; 11	
and longitudinal effects in the DHF group -8dà -4d/0d vs 0dà4d/8d: p=0.016, -12	
8dà -4d/0d vs 4dà8d/12d: p=0.015, -4dà0d/4d vs 4dà8d/12d: p=0.015. Turnover 13	
rate of stable EPB: Longitudinal effects in the control group -8dà -4d/-4dà0d vs 14	
-4dà0d/0dà4d p=0.018; and in the DHF group -8dà -4d/-4dà0d vs 15	
4dà8d/8dà12d: p=0.021. (*) p<0.05; (**) p<0.01 16	
Fig. 6 Structural dynamics of dendritic spines prior and during the chronic DHF 17	
treatment. (a) Real-time 2-photon images of a representative dendrite from a DHF-18	
treated mouse. Arrows point to dendritic spines with a color legend to clarify the effect 19	
on the dynamic parameters. White arrows point to spines that are present from the 20	
beginning of the experiment. Yellow arrows point to spines that are gained in that 21	
imaging session. Blue arrows point to those spines gained in the previous imaging 22	
session that have become stable. Red arrows point to spines that were present in the 23	
previous imaging session but have disappeared in the current one. Scale bar: 10 µm. 24	
(b) Graphs representing the different dynamic parameters. Gain rate: longitudinal 25	
effects in the DHF group -8d/-4d vs 0d-4d: p=0.032; -8d/-4d vs 4d/8d: p=0.037; -26	
4d/0d vs 8d/12d: p=0.018; 0d/4d vs 8d/12d: p=0.018 and 4d/8d vs 8d/12d: p=0.016. 27	
26	
	
Turnover rate: Longitudinal effects in the DHF group -8d/-4d vs -4d/0d: p=0.050; -1	
8d/-4d vs 0d/4d: p=0.027; –4d/0d vs 8d/12d; p=0.036; 0d/4d vs 8d/12d: p=0.027. 2	
Stability rate: Longitudinal effects in the control group -8d/-4d vs 0d/4d: p=0.009; 3	
-8d/-4d vs 4d/8d: p=0.007; -4d/0d vs 0d/4d: p=0.005; -4d/0d vs 4d/8d: p=0.042; and 4	
in the DHF group 8d/-4d vs 0d/4d: p=0.014.  (c) Graphs representing the different 5	
dynamic parameters performed only on stable spines (those that last longer than 4 6	
days). Loss rate of stable spines: Longitudinal effects in the control group -8dà -7	
4d/0d vs -4dà0d/4d: p=0.010; -8dà -4d/0d vs 0dà4d/8d: p=0.004; -8dà -4d/0d vs 8	
4dà8d/12d: p=0.006; and between control and DHF groups 0dà4d/8d: p=0.022 9	
and 4dà8d/12d: p=0.010. Turnover rate of stable spines: Longitudinal effects in 10	
the control group -8dà -4d/-4dà0d vs -4dà0d/0d-4d: p=0.013; -8dà -4d/-4dà0d 11	
vs 0dà4d/4dà8d: p=0.019; -4dà0d/0dà4d vs 4dà8d/8dà12d: p=0.012; and 12	
0dà4d/4dà8d vs 4dà8d/8dà12d: p=0.016. (*) p<0.05; (**) p<0.01 13	
Fig. 7 Real-time analysis of the dendritic spine volume prior and during the DHF 14	
treatment. (a) & (b) Low magnification images of representative dendrites in Control 15	
(a) and DHF-treated (b) animals. Scale bar: 6 µm. (a’) & (b’) High magnification 16	
images from the squared spines from Control (a’) and DHF-treated (b’) animals. Scale 17	
bar: 3 µm. (c) Graph representing the variation (%) in dendritic spine volume. 18	
Longitudinal effects in the control group (-8d) vs 0d p=0.007, (-8d) vs 4d p=0.008, 19	
(-4d) vs 0d p=0.023, (-4d) vs 4d p=0.037 and between control and DHF groups at 20	
4d p=0.014. (*) p<0.05; (**) p<0.01 21	
Fig. 8 Schematic drawing of the results on structural dynamics. Both panels show 22	
a dendrite (upper panel) or an axon (lower panel) before, in the middle of, and by the 23	
end of the DHF or Vehicle treatments.  The addition (+), elimination (-) or stability (=) of 24	
dendritic spines (upper panel) or axonal boutons (lower panel) is represented in order 25	
to simplify the results on structural dynamics.  26	
27	
	
Supplementary figure 1 Absence of gliosis in the cortical region exposed to the 1	
cranial window. (a) Confocal panoramic view of a coronal slice from a THY1-YFP 2	
mouse chronically implanted with a cranial window. The surgery was performed with a 3	
biopsy punch. The edges of the cranial window have been indicated postmortem with 4	
small cuts. A subset of pyramidal neurons constitutively express EYFP (green), the 5	
microglia is labeled with tomato lectin (blue) and the cytoplasm of astrocytes is labeled 6	
with the antibody against S100 (red). Scale bar: 800 µm. (a1) & (a2) are higher 7	
magnification insets inside the window of layer 1 (a1) and layer 5 (a2). (a3) & (a4) are 8	
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